Cargando…

Incorporation of Second-Tier Biomarker Testing Improves the Specificity of Newborn Screening for Mucopolysaccharidosis Type I

Enzyme-based newborn screening for Mucopolysaccharidosis type I (MPS I) has a high false-positive rate due to the prevalence of pseudodeficiency alleles, often resulting in unnecessary and costly follow up. The glycosaminoglycans (GAGs), dermatan sulfate (DS) and heparan sulfate (HS) are both substr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peck, Dawn S., Lacey, Jean M., White, Amy L., Pino, Gisele, Studinski, April L., Fisher, Rachel, Ahmad, Ayesha, Spencer, Linda, Viall, Sarah, Shallow, Natalie, Siemon, Amy, Hamm, J. Austin, Murray, Brianna K., Jones, Kelly L., Gavrilov, Dimitar, Oglesbee, Devin, Raymond, Kimiyo, Matern, Dietrich, Rinaldo, Piero, Tortorelli, Silvia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7422968/ https://www.ncbi.nlm.nih.gov/pubmed/33073008 http://dx.doi.org/10.3390/ijns6010010

Ejemplares similares

The Combined Impact of CLIR Post-Analytical Tools and Second Tier Testing on the Performance of Newborn Screening for Disorders of Propionate, Methionine, and Cobalamin Metabolism
por: Gavrilov, Dimitar K., et al.
Publicado: (2020)

Allelic spectrum of formiminotransferase‐cyclodeaminase gene variants in individuals with formiminoglutamic aciduria
por: Majumdar, Ramanath, et al.
Publicado: (2017)

The low excretor phenotype of glutaric acidemia type I is a source of false negative newborn screening results and challenging diagnoses
por: Guenzel, Adam J., et al.
Publicado: (2021)

367 Designing an Untargeted Metabolomics Assay to Detect Biomarkers for Inborn Errors of Metabolism in the Clinical Laboratory
por: Wurth, Rachel, et al.
Publicado: (2023)

A Comparative Effectiveness Study of Newborn Screening Methods for Four Lysosomal Storage Disorders †
por: Sanders, Karen A., et al.
Publicado: (2020)

Bilateral subdural hematomas and retinal hemorrhages mimicking nonaccidental trauma in a patient with D‐2‐hydroxyglutaric aciduria
por: Perales‐Clemente, Ester, et al.
Publicado: (2020)

Two-Tiered Newborn Screening with Post-Analytical Tools for Pompe Disease and Mucopolysaccharidosis Type I Results in Performance Improvement and Future Direction
por: Hall, Patricia L., et al.
Publicado: (2020)

Role of Tier-0, Tier-1 and Tier-2 Regional Centers in CMS DC04
por: Barrass, T, et al.
Publicado: (2004)

A Tiered Approach for the Evaluation of the Safety of Botanicals Used as Dietary Supplements: An Industry Strategy
por: Roe, Amy L., et al.
Publicado: (2018)

A rapid and non-invasive proteomic analysis using DBS and buccal swab for multiplexed second-tier screening of Pompe disease and Mucopolysaccharidosis type I
por: Zhang, Tong, et al.
Publicado: (2022)

A better start literacy approach: effectiveness of Tier 1 and Tier 2 support within a response to teaching framework
por: Gillon, Gail, et al.
Publicado: (2022)

CMS Experiment Data Processing at RDMS CMS Tier 2 Centers
por: Gavrilov, V, et al.
Publicado: (2012)

Mucopolysaccharidosis VI
por: Valayannopoulos, Vassili, et al.
Publicado: (2010)

Airway Abnormalities in Adult Mucopolysaccharidosis and Development of Salford Mucopolysaccharidosis Airway Score
por: Gadepalli, Chaitanya, et al.
Publicado: (2021)

Phenotypic expansion of ARSK ‐related mucopolysaccharidosis
por: Rustad, Cecilie F., et al.
Publicado: (2022)

The devil in the tiers
por: Feldman, Robin
Publicado: (2021)

Mucopolysaccharidosis IVA: Diagnosis, Treatment, and Management
por: Sawamoto, Kazuki, et al.
Publicado: (2020)

Diagnosing mucopolysaccharidosis IVA
por: Wood, Timothy C., et al.
Publicado: (2013)

Mucopolysaccharidosis-Plus Syndrome
por: Vasilev, Filipp, et al.
Publicado: (2020)

Mucopolysaccharidosis Type I
por: Kubaski, Francyne, et al.
Publicado: (2020)

Hearing Loss in Mucopolysaccharidosis
por: Bicalho, Cibele Gomes, et al.
Publicado: (2021)

A tier-upon-tier march towards the impact factor
por: Martelletti, Paolo
Publicado: (2008)

Example of shared ATLAS Tier2 and Tier3 facilities
por: Gonzalez de la Hoz, S, et al.
Publicado: (2012)

Tier-1 and Tier-2 real-time analysis experience in CMS Data Challenge 2004
por: De Filippis, N, et al.
Publicado: (2004)

A tiered approach to pharmacokinetic studies.
por: Wilson, A G, et al.
Publicado: (1994)

Mucopolysaccharidosis Type II: A Kenyan Case Series
por: Mungai, L. N. Wainaina, et al.
Publicado: (2021)

Atlas operation in the GridKa Tier1/Tier2 Cloud
por: Nderitu, S, et al.
Publicado: (2010)

Atlas operation in the GridKa Tier1/Tier2 Cloud
por: Nderitu, S, et al.
Publicado: (2011)

Exporting Raw/ESD data from Tier-0 $\to$ Tier-1s
por: Bärring, O
Publicado: (2004)

Validation and Implementation of a Highly Sensitive and Efficient Newborn Screening Assay for Mucopolysaccharidosis Type II
por: Bilyeu, Heather, et al.
Publicado: (2020)

Respiratory and sleep disorders in mucopolysaccharidosis
por: Berger, Kenneth I., et al.
Publicado: (2012)

Anaesthesia and airway management in mucopolysaccharidosis
por: Walker, Robert, et al.
Publicado: (2012)

Osteoarthropathy in mucopolysaccharidosis type II
por: NASCU, IOANA, et al.
Publicado: (2013)

From hypertransaminasemia to mucopolysaccharidosis IIIA
por: Krawiec, Paulina, et al.
Publicado: (2014)

Audiometric evaluation in individuals with mucopolysaccharidosis
por: da Silveira, Marcela Rosana Maia, et al.
Publicado: (2018)

Mucopolysaccharidosis: A broad review
por: Nagpal, Ritu, et al.
Publicado: (2022)

Audiologic evaluations of children with mucopolysaccharidosis()
por: Gökdoğan, Çağıl, et al.
Publicado: (2015)

Visual impairment in mucopolysaccharidosis VI
por: Magalhães, Augusto Monteiro, et al.
Publicado: (2023)

Revue tiers monde.
Publicado: (1960)

Atlas Tier 3
por: Benjamin, D
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_vnfjo0ccqfran7vsm9c5o9pkgk